Core for COVID-19 Cohort IMPACC

COVID-19 队列 IMPACC 核心

基本信息

  • 批准号:
    10265707
  • 负责人:
  • 金额:
    $ 95.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-05-14 至 2023-11-30
  • 项目状态:
    已结题

项目摘要

The overall goal of the Human Immunology Project Consortium (HIPC) program is to capitalize on recent advances in immune profiling methods in order to create a novel public resource that characterizes diverse states of the human immune system. We propose to contribute to this program through deep interrogation and a broad systems approach that will identify molecular signatures of divergent human immune responses to infections. The three projects that comprise our U19 each leverage a common experimental infrastructure to focus on a different infectious diseases: the Lyme disease spirochete Borrelia burgdorferi, emerging arthropod-borne West Nile virus, and effects of aging on vaccination against influenza. Our goal is to delineate human immune signatures that are associated with the divergent manifestations in the population, using well-defined patient cohorts and a multidimensional analytical approach to quantitatively assess primary human immune cell function. Our program employs cutting-edge immune profiling such as multidimensional profiling by CyTOF, metabolomics, nanoscale technologies such as MuSIC (MultiSpectral Imaging Cytometry), and RNA-seq on single cells that will inform a systems approach to elucidate the biologic signatures defining immune responsiveness. Commonalities between the responses in different tissues, and to the different infection types, will be determined by quantifying signature enrichments, and by identifying conserved active sub-networks in this immune-specific functional network. This collaborative U19 takes advantage of enormous strengths across our institutions to tackle a challenging issue in human immunology. The investigators in this proposal have established collaborations, regular interactions, and a track record of shared success. Our three research projects are supported by shared cores for Administration, Data Management and Analysis, Single Cell Immunophenotyping, and Clinical Recruitment. The united goal of these varied approaches is to define elements of the immune response that contribute to divergent infection outcomes. This multifactorial, wide-angle view of the immune response will be compiled employing the expertise of each individual approach for Systems Modeling from deep interrogation of three sets of stratified patient cohorts. The output of this functional systems immunology approach will be definitions of human immune signatures following multiple forms of infectious challenges with the ultimate goal of defining future targets for intervention and predicting susceptibility or resistance.
人类免疫学项目联盟(HIPC)计划的总体目标是利用最近的研究成果

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David A. Hafler其他文献

Increased IL-12 production in progressive multiple sclerosis: Induction by activated CD4+ T cells via CD40 ligand
进行性多发性硬化症中 IL-12 的产生增加:通过 CD40 配体诱导活化的 CD4 T 细胞
  • DOI:
    10.1177/135245859600200519
  • 发表时间:
    1996
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Howard L. Weiner;Konstantin E. Balashov;Derek R. Smith;Samia J. Khoury;David A. Hafler
  • 通讯作者:
    David A. Hafler
Insulin auto-antigenicity in type 1 diabetes (Reply)
1 型糖尿病中的胰岛素自身抗原性(回复)
  • DOI:
    10.1038/nature04424
  • 发表时间:
    2005-11-23
  • 期刊:
  • 影响因子:
    48.500
  • 作者:
    David A. Hafler;Sally C. Kent;Yahua Chen;Lisa Bregoli;Sue M. Clemmings;Bernhard Hering;Norma Sue Kenyon;Camillo Ricordi
  • 通讯作者:
    Camillo Ricordi
FOXP3+ regulatory T cells in the human immune system
人类免疫系统中的 FOXP3+调节性 T 细胞
  • DOI:
    10.1038/nri2785
  • 发表时间:
    2010-06-18
  • 期刊:
  • 影响因子:
    60.900
  • 作者:
    Shimon Sakaguchi;Makoto Miyara;Cristina M. Costantino;David A. Hafler
  • 通讯作者:
    David A. Hafler
Antigen-driven peripheral immune tolerance. Suppression of organ-specific autoimmune diseases by oral administration of autoantigens.
抗原驱动的外周免疫耐受。
  • DOI:
    10.1007/978-3-642-51479-1_81
  • 发表时间:
    1991
  • 期刊:
  • 影响因子:
    5.2
  • 作者:
    Howard L. Weiner;Howard L. Weiner;Howard L. Weiner;Ariel Miller;Ariel Miller;Ariel Miller;Samia J. Khoury;Samia J. Khoury;Samia J. Khoury;Z. J. Zhang;Z. J. Zhang;Z. J. Zhang;Ahmad Al;Ahmad Al;Ahmad Al;Stanley A. Brod;Stanley A. Brod;Stanley A. Brod;Ofer Lider;Ofer Lider;Ofer Lider;Paul A. T. Higgins;Paul A. T. Higgins;Paul A. T. Higgins;Raymond A. Sobel;Raymond A. Sobel;Raymond A. Sobel;Makoto Matsui;Makoto Matsui;Makoto Matsui;Mohamed H. Sayegh;Mohamed H. Sayegh;Mohamed H. Sayegh;Charles C. J. Carpenter;Charles C. J. Carpenter;Charles C. J. Carpenter;George Eisenbarth;George Eisenbarth;George Eisenbarth;R. Nussenblatt;R. Nussenblatt;R. Nussenblatt;David A. Hafler;David A. Hafler;David A. Hafler
  • 通讯作者:
    David A. Hafler
Functional Characterization of Autoreactive T-cells in Acute Disseminated Encephalomyelitis 199
急性播散性脑脊髓炎中自身反应性 T 细胞的功能特征 199
  • DOI:
    10.1203/00006450-199609000-00222
  • 发表时间:
    1996-09-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Annette Pohi-Koppe;Sandra K. Burchett;David A. Hafler
  • 通讯作者:
    David A. Hafler

David A. Hafler的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David A. Hafler', 18)}}的其他基金

Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122
靶向胶质母细胞瘤中的 T 细胞功能障碍:抗 TIGIT 抗体 AB154 与抗 PD1 抗体 AB122 联合的概念验证 0/I 期试验
  • 批准号:
    10346649
  • 财政年份:
    2022
  • 资助金额:
    $ 95.5万
  • 项目类别:
Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122
靶向胶质母细胞瘤中的 T 细胞功能障碍:抗 TIGIT 抗体 AB154 与抗 PD1 抗体 AB122 联合的概念验证 0/I 期试验
  • 批准号:
    10573141
  • 财政年份:
    2022
  • 资助金额:
    $ 95.5万
  • 项目类别:
Systems Immune Profiling of Divergent Responses to Infection
对感染的不同反应的系统免疫分析
  • 批准号:
    10265709
  • 财政年份:
    2020
  • 资助金额:
    $ 95.5万
  • 项目类别:
Systems Immune Profiling of Divergent Responses to Infection
对感染的不同反应的系统免疫分析
  • 批准号:
    10205567
  • 财政年份:
    2020
  • 资助金额:
    $ 95.5万
  • 项目类别:
COVID-19 Supplement: Systems Immune Profiling of Divergent Responses to Infection
COVID-19 补充:对感染的不同反应的系统免疫分析
  • 批准号:
    10265708
  • 财政年份:
    2020
  • 资助金额:
    $ 95.5万
  • 项目类别:
Immunophenotyping for COVID-19 Cohort (IMPACC)
COVID-19 队列的免疫表型分析 (IMPACC)
  • 批准号:
    10265706
  • 财政年份:
    2020
  • 资助金额:
    $ 95.5万
  • 项目类别:
Yale Clinical Neuroscientist Training Program
耶鲁大学临床神经科学家培训计划
  • 批准号:
    10333938
  • 财政年份:
    2012
  • 资助金额:
    $ 95.5万
  • 项目类别:
Yale Clinical Neuroscientist Training Program
耶鲁大学临床神经科学家培训计划
  • 批准号:
    10210303
  • 财政年份:
    2012
  • 资助金额:
    $ 95.5万
  • 项目类别:
The role of the innate immune system on Treg reprogramming in human autoimmune di
先天免疫系统在人类自身免疫性疾病中 Treg 重编程中的作用
  • 批准号:
    8495933
  • 财政年份:
    2012
  • 资助金额:
    $ 95.5万
  • 项目类别:
Yale Clinical Neuroscientist Training Program
耶鲁大学临床神经科学家培训计划
  • 批准号:
    8331031
  • 财政年份:
    2012
  • 资助金额:
    $ 95.5万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 95.5万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 95.5万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 95.5万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 95.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 95.5万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 95.5万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 95.5万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 95.5万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 95.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 95.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了